Abivax $ABVX fell more than 30% after investors focused on cancer-case details in Phase 3 ABTECT maintenance data, despite placebo-adjusted clinical remission rates of 39.3% and 40.3% for 25 mg and 50 mg obefazimod. The company still targets an FDA NDA submission in late Q4 2026.
Victoria’s Secret $VSXY rose about 40% after Q1 adjusted EPS of $0.60 beat its $0.20-$0.30 guide and net sales rose 15% to $1.560B. The retailer raised FY2026 net-sales guidance to $7.030B-$7.130B and adjusted operating-income guidance to $550M-$580M.
Hewlett Packard Enterprise rose about 30% after fiscal Q2 revenue reached $10.7B, up 40% year over year, and non-GAAP EPS of $0.79 topped the company outlook. The company also raised FY26 revenue growth guidance to 29%-33% and free-cash-flow guidance to at least $3.5B.
WTI rose $2.93 to $90.29 and Brent added $2.52 to $93.64 after a fresh U.S.-Iran exchange of strikes. The move keeps the Strait of Hormuz risk premium inside inflation, rates, and energy-equity pricing.
$6.8B of equity value and an $8.5B enterprise value put Taylor Morrison $TMHC inside Berkshire Hathaway at $72.50 a share. The cash offer is 24% above the May 29 close of $58.50 and clears the Tier-1 M&A threshold.
The SEC proposed rescinding its 2024 climate-disclosure rules in full, opening a 60-day comment period after Federal Register publication. The action would remove greenhouse-gas, climate-risk and severe-weather disclosure mandates from registration statements and annual reports if finalized.
Kohl's $KSS rose 20% after Q1 FY2026 net sales fell 1.7% to $3.0B but comparable sales declined only 1.1%, the retailer's best trend in more than four years. The company affirmed FY2026 adjusted EPS guidance of $1.00-$1.60 and reported inventory down 8% year over year.
Best Buy $BBY climbed 15% after Q1 FY2027 comparable sales increased 2.0%, revenue reached $8.936B, and diluted EPS rose 38% to $1.31. The retailer reiterated FY2027 adjusted EPS guidance of $6.30-$6.60 and named Jason Bonfig as incoming CEO effective November 1, 2026.
Okta $OKTA rose 8% after Q1 FY2027 revenue grew 11% to $765M and remaining performance obligations increased 16% to $4.719B. The identity-software company guided FY2027 revenue to $3.185B-$3.205B and free cash flow to $855M-$885M.
SentinelOne $S fell 8% after Q1 FY2027 results showed 21% revenue growth to $277M, 23% ARR growth to $1.163B, and a restructuring plan tied to AI and cloud-security investment. The company raised non-GAAP operating-income guidance but guided Q2 revenue to $289M-$291M and FY2027 revenue to $1.195B-$1.205B.
Innovent Biologics (01801.HK) rose about 11% after Pfizer $PFE agreed to a global oncology collaboration worth up to $10.5B. The package includes a $650M upfront payment and up to $9.85B in milestone payments.
International Flavors & Fragrances $IFF agreed to sell its Food Ingredients business to CVC for about $4.3B, above the $500M Tier-1 M&A threshold. The unit generated nearly $3.1B of 2025 sales and about $430M of EBITDA.